8-K: Gossamer Bio Announces Positive Financial Results and Business Update: PROSERA Phase 3 Trial on Track

Gossamer Bio reports its Q4 and full-year 2024 financial results, highlighting progress with Seralutinib and a strong cash position.

Summary

• Gossamer Bio announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is focused on developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
• Topline results from the PROSERA Phase 3 study in PAH are expected in the fourth quarter of 2025.
• A registrational Phase 3 clinical trial in PH-ILD is expected to commence in the second half of 2025.
• Seralutinib received Orphan Drug Designation for PAH in Japan.
• Cash, cash equivalents, and marketable securities totaled $294.5 million at year-end 2024.
• The company believes this is sufficient to fund operations into the first half of 2027.
• The net loss for the full year ended December 31, 2024, was $56.5 million, or $0.25 per share, compared to a net loss of $179.8 million, or $1.18 per share, for the full year ended December 31, 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress of seralutinib, the strong cash position, and the reduced net loss. However, the inherent risks in drug development and regulatory approval temper the overall sentiment.

Positives

• Seralutinib received Orphan Drug Designation in Japan for PAH, potentially expediting regulatory review and market access.
• The company has a strong cash position of $294.5 million, providing a runway into the first half of 2027.
• Net loss decreased significantly from $179.8 million in 2023 to $56.5 million in 2024, indicating improved financial performance.
• The PROSERA Phase 3 study is on track, with topline results expected in Q4 2025.
• The company expects to activate clinical sites for a registrational Phase 3 PH-ILD clinical trial in the second half of 2025.

Negatives

• The company reported a net loss of $56.5 million for the full year ended December 31, 2024, although this is a significant improvement compared to the previous year's loss of $179.8 million.

Risks

• The success of seralutinib depends on the outcome of clinical trials, which are subject to inherent risks and uncertainties.
• Regulatory approvals are not guaranteed and may be delayed or denied.
• The company faces competition from other companies developing treatments for PAH and PH-ILD.
• Unexpected adverse side effects or inadequate efficacy of seralutinib may limit its development, regulatory approval and/or commercialization.
• Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may adversely affect our business and financial condition and the broader economy and biotechnology industry.

Future Outlook

Gossamer Bio anticipates topline results from the PROSERA Phase 3 study in PAH in the fourth quarter of 2025 and expects to commence a Phase 3 clinical trial in PH-ILD in the second half of 2025. The company believes its current cash position will fund operations into the first half of 2027.

Management Comments

• Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio, stated he is both humbled and energized by the progress Gossamer has made in its mission to improve the lives of pulmonary hypertension patients.
• He believes that seralutinib has the potential to reshape the treatment paradigm for pulmonary hypertension.
• The Gossamer team remains intensely focused on execution of the PROSERA Study to ensure topline results by end of the year.

Industry Context

Gossamer Bio is operating in the competitive biopharmaceutical industry, specifically targeting pulmonary hypertension. The Orphan Drug Designation for seralutinib in Japan could provide a competitive advantage. The company's focus on seralutinib and its potential to address unmet needs in PAH and PH-ILD positions it within a growing market for pulmonary hypertension treatments.

Comparison to Industry Standards

• Gossamer Bio's focus on seralutinib, a PDGFR, CSF1R, and c-KIT inhibitor, aligns with industry trends in targeting multiple pathways in pulmonary hypertension.
• Companies like United Therapeutics and Acceleron Pharma (now part of Merck) have achieved success with targeted therapies for PAH, setting a benchmark for Gossamer Bio.
• The planned Phase 3 trial in PH-ILD reflects a growing recognition of the need for effective treatments for this specific form of pulmonary hypertension, an area where treatment options are currently limited.
• The company's cash runway into the first half of 2027 is a positive sign, providing financial stability to advance its clinical programs.

Stakeholder Impact

• Positive for shareholders due to the progress of seralutinib and the strong cash position.
• Potential benefit for patients with PAH and PH-ILD if seralutinib proves to be an effective treatment.
• Positive for employees due to the company's financial stability and ongoing clinical programs.

Next Steps

• Continue enrollment in the PROSERA Phase 3 study in PAH.
• Prepare for topline results from the PROSERA study, expected in Q4 2025.
• Activate clinical sites for a registrational Phase 3 PH-ILD clinical trial in the second half of 2025.
• Pursue regulatory approval for seralutinib in Japan based on clinical trial results.

Key Dates